Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP decreased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 1.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 588,599 shares of the company's stock after selling 11,662 shares during the quarter. Dimensional Fund Advisors LP owned 2.05% of Krystal Biotech worth $92,214,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech during the 3rd quarter valued at approximately $40,000. Covestor Ltd lifted its holdings in Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after purchasing an additional 642 shares in the last quarter. Avanza Fonder AB acquired a new stake in shares of Krystal Biotech in the fourth quarter valued at about $119,000. KBC Group NV grew its position in shares of Krystal Biotech by 46.3% in the fourth quarter. KBC Group NV now owns 939 shares of the company's stock valued at $147,000 after purchasing an additional 297 shares during the period. Finally, Blue Trust Inc. increased its stake in shares of Krystal Biotech by 74.4% during the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after purchasing an additional 433 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Analyst Upgrades and Downgrades

KRYS has been the topic of several research analyst reports. Citigroup lifted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. Chardan Capital increased their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price on the stock. Finally, HC Wainwright increased their target price on shares of Krystal Biotech from $221.00 to $240.00 and gave the company a "buy" rating in a research report on Monday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $222.71.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 13.70% of the company's stock.

Krystal Biotech Stock Up 0.3 %

Shares of Krystal Biotech stock traded up $0.47 during mid-day trading on Friday, hitting $166.16. The stock had a trading volume of 228,173 shares, compared to its average volume of 294,918. The firm has a market cap of $4.80 billion, a P/E ratio of 55.57 and a beta of 0.75. The firm has a 50-day moving average of $175.22 and a two-hundred day moving average of $171.38. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm's quarterly revenue was up 116.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.30 earnings per share. Sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).